Bcr-TMP, a novel nanomolar-active compound that exhibits both MYB-and microtubule-inhibitory activity

Maria V. Yusenko, Abhiruchi Biyanee, Daria Frank, Leonhard H.F. Köhler, Mattias K. Andersson, Cyrus Khandanpour, Rainer Schobert, Göran Stenman, Bernhard Biersack, Karl Heinz Klempnauer*

*Corresponding author for this work
8 Citations (Scopus)

Abstract

Studies of the role of MYB in human malignancies have highlighted MYB as a potential drug target for acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). Here, we present the initial characterization of 2-amino-4-(3,4,5-trimethoxyphenyl)-4H-naphtho[1,2-b]pyran-3-carbonitrile (Bcr-TMP), a nanomolar-active MYB-inhibitory compound identified in a screen for novel MYB inhibitors. Bcr-TMP affects MYB function in a dual manner by inducing its degradation and suppressing its transactivation potential by disrupting its cooperation with co-activator p300. Bcr-TMP also interferes with the p300-dependent stimulation of C/EBPβ, a transcription factor cooperating with MYB in myeloid cells, indicating that Bcr-TMP is a p300-inhibitor. Bcr-TMP reduces the viability of AML cell lines at nanomolar concentrations and induces cell-death and expression of myeloid differentiation markers. It also down-regulates the expression of MYB target genes and exerts stronger anti-proliferative effects on MYB-addicted primary murine AML cells and patient-derived ACC cells than on their non-oncogenic counterparts. Surprisingly, we observed that Bcr-TMP also has microtubule-disrupting activity, pointing to a possible link between MYB-activity and microtubule stability. Overall, Bcr-TMP is a highly potent multifunctional MYB-inhibitory agent that warrants further investigation of its therapeutic potential and mechanism(s) of action.

Original languageEnglish
Article number43
JournalCancers
Volume14
Issue number1
ISSN2072-6694
DOIs
Publication statusPublished - 01.01.2022

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 2.22-14 Hematology, Oncology

Fingerprint

Dive into the research topics of 'Bcr-TMP, a novel nanomolar-active compound that exhibits both MYB-and microtubule-inhibitory activity'. Together they form a unique fingerprint.

Cite this